{"id":77538,"date":"2026-08-31T14:19:30","date_gmt":"2026-08-31T06:19:30","guid":{"rendered":"https:\/\/flcube.com\/?p=77538"},"modified":"2026-08-31T14:19:30","modified_gmt":"2026-08-31T06:19:30","slug":"glubios-glb-005-wiz-degrader-enters-nmpa-rare-disease-pilot-for-%ce%b2-thalassemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77538","title":{"rendered":"GluBio&#8217;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GluBio Pharmaceuticals<\/strong> announced that <strong>GLB\u2011005<\/strong>, its self\u2011developed widely interspaced zinc finger (<strong>WIZ<\/strong>) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the <strong>Center for Drug Evaluation (CDE)<\/strong> of the <strong>National Medical Products Administration (NMPA)<\/strong> pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called <strong>&#8220;Care Program\u2011Extension.&#8221;<\/strong> The designation provides accelerated regulatory engagement for one of China&#8217;s earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>Center for Drug Evaluation (CDE), NMPA<\/strong><\/td><\/tr><tr><td>Designation<\/td><td>&#8220;Care Program\u2011Extension&#8221; rare disease pilot scheme inclusion<\/td><\/tr><tr><td>Product<\/td><td><strong>GLB\u2011005<\/strong>, WIZ molecular glue protein degrader<\/td><\/tr><tr><td>Lead Indication<\/td><td>Transfusion\u2011dependent \u03b2\u2011thalassemia<\/td><\/tr><tr><td>Broader Indications<\/td><td>\u03b2\u2011hemoglobinopathies including sickle cell disease<\/td><\/tr><tr><td>Date<\/td><td>31 Aug 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Accelerated regulatory engagement and clinical advancement under the NMPA pilot scheme<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> GLB\u2011005 \u2014 a potent, highly selective WIZ molecular glue protein degrader<\/li>\n\n\n\n<li><strong>Target:<\/strong> WIZ (widely interspaced zinc finger protein), a repressor of fetal hemoglobin (HbF)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Mediates ubiquitination and proteasomal degradation of WIZ via the CRBN E3 ubiquitin ligase<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Efficiently induces upregulation of HbF expression to compensate for defective adult hemoglobin<\/li>\n\n\n\n<li><strong>Target Diseases:<\/strong> \u03b2\u2011hemoglobinopathies, including but not limited to transfusion\u2011dependent \u03b2\u2011thalassemia and sickle cell disease<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Applies molecular glue degrader technology to hemoglobin reactivation \u2014 a differentiated approach within the HbF\u2011induction landscape<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-regulatory-context\" class=\"wp-block-heading\">Clinical Evidence \u2013 Regulatory Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Program<\/td><td>NMPA &#8220;Care Program\u2011Extension&#8221; pilot for innovative rare disease drugs<\/td><\/tr><tr><td>Significance<\/td><td>Signals regulatory prioritization and pathway support for GLB\u2011005 development<\/td><\/tr><tr><td>Patient Population<\/td><td>Transfusion\u2011dependent \u03b2\u2011thalassemia patients in China, where disease burden remains substantial<\/td><\/tr><tr><td>Unmet Need<\/td><td>Durable, non\u2011transplant therapeutic options that reduce or eliminate transfusion dependence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The CDE inclusion marks a meaningful regulatory validation for <strong>GluBio Therapeutics<\/strong>, aligning <strong>GLB\u2011005<\/strong> with China&#8217;s national priority to expand innovative treatment options for rare diseases. For a molecular glue degrader in a genetically defined rare indication, early regulatory engagement under the pilot scheme can materially compress development timelines.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Policy Tailwind:<\/strong> China&#8217;s CDE pilot scheme reflects accelerating regulatory commitment to rare disease innovation, with expedited pathways gaining momentum<\/li>\n\n\n\n<li><strong>Differentiated Modality:<\/strong> Molecular glue degraders remain a frontier technology; a selective WIZ degrader for HbF induction offers a novel mechanism versus existing thalassemia therapies<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Positions GLB\u2011005 alongside gene therapies and other HbF\u2011induction strategies, with a small\u2011molecule\u2011adjacent convenience advantage<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Strengthens GluBio&#8217;s platform credibility and partnership potential in the crowded \u03b2\u2011hemoglobinopathy space<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding GLB\u2011005&#8217;s regulatory progress and clinical development under the NMPA pilot scheme. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[102,2131,24],"class_list":["post-77538","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-cde","tag-glubio-pharmaceutical","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GluBio&#039;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called &quot;Care Program\u2011Extension.&quot; The designation provides accelerated regulatory engagement for one of China&#039;s earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77538\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GluBio&#039;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia\" \/>\n<meta property=\"og:description\" content=\"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called &quot;Care Program\u2011Extension.&quot; The designation provides accelerated regulatory engagement for one of China&#039;s earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77538\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T06:19:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GluBio&#8217;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia\",\"datePublished\":\"2026-08-31T06:19:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\",\"GluBio Pharmaceutical\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77538#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77538\",\"name\":\"GluBio's GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-31T06:19:30+00:00\",\"description\":\"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called \\\"Care Program\u2011Extension.\\\" The designation provides accelerated regulatory engagement for one of China's earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77538\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77538#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GluBio&#8217;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GluBio's GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia - Insight, China&#039;s Pharmaceutical Industry","description":"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called \"Care Program\u2011Extension.\" The designation provides accelerated regulatory engagement for one of China's earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77538","og_locale":"en_US","og_type":"article","og_title":"GluBio's GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia","og_description":"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called \"Care Program\u2011Extension.\" The designation provides accelerated regulatory engagement for one of China's earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.","og_url":"https:\/\/flcube.com\/?p=77538","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T06:19:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77538#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77538"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GluBio&#8217;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia","datePublished":"2026-08-31T06:19:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77538"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE","GluBio Pharmaceutical","Rare \/ orphan disease drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77538#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77538","url":"https:\/\/flcube.com\/?p=77538","name":"GluBio's GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-31T06:19:30+00:00","description":"GluBio Pharmaceuticals announced that GLB\u2011005, its self\u2011developed widely interspaced zinc finger (WIZ) molecular glue degrader for transfusion\u2011dependent \u03b2\u2011thalassemia, has been included in the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases \u2014 the so\u2011called \"Care Program\u2011Extension.\" The designation provides accelerated regulatory engagement for one of China's earliest clinical\u2011stage molecular glue degraders targeting \u03b2\u2011hemoglobinopathies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77538#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77538"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77538#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GluBio&#8217;s GLB\u2011005 WIZ Degrader Enters NMPA Rare Disease Pilot for \u03b2\u2011Thalassemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77538"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77538\/revisions"}],"predecessor-version":[{"id":77540,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77538\/revisions\/77540"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}